Tirzepatide produces significantly more weight loss than semaglutide. In the SURMOUNT-5 trial, the first head-to-head comparison of the two drugs, participants on tirzepatide lost 20.2% of their body weight over 72 weeks compared to 13.7% for those on semaglutide. That’s roughly a 50% greater effect, which in practical terms means someone starting at 250 pounds could expect to lose about 50 pounds on tirzepatide versus 34 pounds on semaglutide.
Both drugs are weekly injections approved by the FDA for weight management, and both work in similar ways. But they’re not identical, and the differences go beyond the number on the scale.
Why Tirzepatide Produces More Weight Loss
The key difference is biological. Semaglutide (sold as Wegovy for weight loss and Ozempic for diabetes) targets one gut hormone receptor called GLP-1. Tirzepatide (sold as Zepbound for weight loss and Mounjaro for diabetes) targets two: GLP-1 and a second receptor called GIP. Both of these are natural hormones your body releases after eating, and they influence appetite, blood sugar, and how quickly food moves through your digestive system.
The shared effects of both drugs include stimulating insulin release when blood sugar is elevated, reducing sugar production by the liver, and slowing stomach emptying so you feel full longer. That last effect is the main driver of weight loss for most people. You simply feel less hungry and get satisfied with smaller portions.
What tirzepatide adds through GIP activation isn’t fully understood yet, but the clinical results consistently show it amplifies the weight loss effect beyond what GLP-1 alone achieves. The dual-receptor approach appears to suppress appetite more effectively and may influence how the body stores and burns fat, though researchers are still working out the precise mechanisms.
What the Numbers Look Like Over Time
SURMOUNT-5 ran for 72 weeks, about a year and a half, and enrolled adults with obesity or overweight who did not have diabetes. Participants on tirzepatide reached an average of 20.2% body weight reduction, while those on semaglutide reached 13.7%. Both groups followed the same general lifestyle guidance during the trial.
To put those numbers in context, a 13.7% loss is already considered a strong clinical outcome. Before these medications existed, most diet and exercise programs produced 5 to 10% weight loss at best. Semaglutide was considered a breakthrough when it arrived. Tirzepatide simply moved the bar further.
Neither drug works instantly. Both require gradual dose increases over several months. Semaglutide starts at 0.25 mg per week and increases by 0.25 mg every four weeks until reaching the maintenance dose of 2.4 mg, a process that takes 16 to 20 weeks. Tirzepatide starts at 2.5 mg and increases by 2.5 mg every four weeks up to a maximum of 15 mg. Most of the weight loss happens during and after the titration period, with results continuing to improve through the first year or longer.
Side Effects Are Similar for Both
The most common side effects of both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. These tend to be worst during dose increases and often improve as your body adjusts. The gradual titration schedule exists specifically to reduce these effects.
Because tirzepatide uses higher relative doses and targets an additional receptor, some people assume it causes worse side effects. In practice, the gastrointestinal profiles in clinical trials have been broadly comparable between the two drugs at their maintenance doses. Most participants in both groups experienced some nausea early on, but serious side effects leading to discontinuation were relatively uncommon for either medication.
The FDA recently approved a higher 7.2 mg dose of semaglutide (called Wegovy HD), and at that dose, reports of altered skin sensation, described as sensitivity, pain, or burning, were more common than at lower doses, though they generally resolved on their own. Both drugs carry a boxed warning about potential thyroid tumor risk based on animal studies, and neither should be used by people with a personal or family history of medullary thyroid cancer.
Both Drugs Cause Some Muscle Loss
One concern with any rapid weight loss is losing muscle along with fat. A systematic review of body composition data found that with GLP-1 based medications, lean mass loss accounted for about 25% of total weight lost. So for every four pounds dropped, roughly one pound comes from lean tissue rather than fat. This ratio held for both tirzepatide at 15 mg and semaglutide at 2.4 mg, and notably, both were among the least effective options in the drug class at preserving lean mass.
This doesn’t mean the drugs are harmful to muscle per se. Losing some lean mass during significant weight loss is expected regardless of how you lose it. But it does mean that resistance training and adequate protein intake matter, especially for older adults or anyone losing large amounts of weight. The fat loss still far outweighs the muscle loss in absolute terms.
Cost and Access
Both medications are expensive, though recent price cuts have brought them closer to each other. Novo Nordisk reduced Wegovy’s list price by 23% to $499 per month for people without insurance coverage. Eli Lilly cut Zepbound’s starter dose to $349 per month, with higher maintenance doses costing $499 per month through its self-pay program.
Insurance coverage remains inconsistent. Many private insurers and Medicare plans still do not cover weight loss medications, or they impose strict eligibility criteria like a minimum BMI threshold or documented failure of other weight loss methods. If your insurance does cover one of these drugs, it may cover only one and not the other, which can effectively make the choice for you. Checking your specific plan’s formulary is the fastest way to find out what’s available to you at a copay rather than full price.
Choosing Between the Two
If your primary goal is maximum weight loss and both drugs are equally available to you, the clinical evidence favors tirzepatide. A 20% weight loss versus 14% is a meaningful difference, especially for people whose weight-related health conditions, like sleep apnea, joint pain, or type 2 diabetes risk, improve in proportion to how much weight they lose.
That said, semaglutide has a longer track record. It has been on the market longer, has more published data on cardiovascular outcomes, and now offers more dosing flexibility with the recently approved higher-dose option. Some people also respond exceptionally well to semaglutide and achieve results at the higher end of what trials show.
Individual response varies. Clinical trial averages don’t predict exactly what will happen for any one person. Factors like starting weight, metabolic health, diet, activity level, and genetics all influence results. Some people plateau on one medication and do better switching to the other. Both drugs represent a significant advance over what was previously available, and the “worse” option here still produces weight loss that would have been considered remarkable just a few years ago.